Armotraz tablets are indicated for supporting treatment of postmenopausal women with hormone receptor positive breast cancer.
Armotraz tablets which consist of an active composition like anastrazole. Anastrazole is categorized as inhibitor of non-steroidal Aromatase. And which available in the form of tablet
Armotraz is able to decrease the production of estrogen by prohibiting Aromatase, an enzyme fundamental for changes of androgen into estrogen Anastrazole is includes in hormonal treatment. It is prescription drugs which is used under the guidance of pharmacist.
Armotraz tablets are indicated for supporting treatment of postmenopausal women with hormone receptor positive breast cancer. Armotraz is indicated for first line therapy in post menopausal women having receptor positive or hormone receptor exotic locally progressive or metastatic breast carcinoma Armotraz tablets indicated for second line therapy in patients having metastatic breast cancer, in post menopausal women with cancer advancement consequently tamoxifen treatment. Treatment infrequently reacted to Armotraz tablets in Patients with hormone receptor negative disorder, or patient who are not reacting to tamoxifen .
MECHANISM OF ACTION
Anastrazole Simultaneously inhibits Aromatase, which an enzyme helped for changing of ambient estrogen to estrone through adrenally growth androstenedione by Aromatase in peripheral tissues Thereby the prevention of Aromatase may leads to reduced in plasma and malignant assembly of estrogen, following to lowering of tumor lump or slow the progress of tumor growth
Rapidly absorption occurs and attains high plasma concentration occurs within 2 hours. Effects of food: food will decrease the rate but not all the extent of anastrazole absorption.
The drug anastrazole has human serum protein bound is 40%
The anastrazole metabolism is occurred via N-Dealkylation, hydroxylation and Glucuronidation The metabolites of anastrazole are; Triazole-major circulating metabolite which has poor pharmacological activity A glucoronide conjugate of hydroxyl anastrazole A glucoronide conjugate of anastrazole
Nearly 85% of anastrazole reclaimed in feces and urine in Hepatic metabolism: 10% total clearance in Renal metabolism The anastrazole half life is 50 hours
The Armotraz tablet usual dosage is 1mg should administrated as a single dose by given with or without food In the metastatic breast cancer condition of, Armotraz should be taken until disease improvement Armotraz should be followed for five years in ATAC trials In renal impairment patients or for elderly patients no dose adjustments acquired In mild to moderate hepatic impairment condition no dose adjustment takes place.
Condition of ischemic cardiovascular action: There is a chance of raising of proportion of ischemic cardiovascular effects while getting Armotraz tablets. Decreased total hip bone density and lumbar spine density when patients receiving Armotraz tablet have chance of getting Cholesterol: The patient receiving tamoxifen may have elevate serum cholesterol level correlated by Armotraz tablets
Common side effects
Asthenia, pain, back pain, headache, abdominal pain, infection, injury, flu like syndrome, chest pain, neoplasm, cystitis
Nausea, constipation, diarrhea, dyspepsia, GI disorders
Blood related effects
Lymph edema, anemia
Peripheral edema, weight gain, hypercholesterolemia
Arthritis, arthralgia, osteoporosis, fracture, bone pain, arthrosis, joint pain, Myalgia
Depression, insomnia, dizziness, anxiety, paresthesia
Pharyngitis, cough increased, dyspnea, sinusitis, bronchitis
urinary tract infection, breast pain, breast neoplasm, vulvovaginitis, vaginal hemorrhage, vaginitis ; Leucorrhea
While interaction of tamoxifen with anastrazole leads to reduce the plasma concentration of anastrazole by 27% Not concomitant use with Armotraz tablet which may cause depletion of its pharmacological activity in Estrogen therapy Interaction of Warfarin with anastrazole, it did not alter the anti-coagulant effect Armotraz tablet will change the effect of other drugs, it concluded as CYP-450 prohibition
PREGNANCY & LACTATION
Pregnancy category of anastrazole: X For pregnancy condition and breast feeding mothers the drug Armotraz tablets should not be recommended because causes fetal death.
Stored between 20°C to 25°C (68°F to 77°F) at controlled room temperature. Protect carton away from heat, moisture, and light.
The dose missed by patient should have the dose immediately before the next dose timing reaches , or leave the missed dose and continue the regular schedule. Remember do not have double dose at a time Please consult with doctor for further details.